



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/617,568	07/11/2003	Kai W. Wucherpennig	DFN-044	3949

25181 7590 08/24/2007  
FOLEY HOAG, LLP  
PATENT GROUP, WORLD TRADE CENTER WEST  
155 SEAPORT BLVD  
BOSTON, MA 02110

EXAMINER
DIBRINO, MARIANNE NMN

ART UNIT	PAPER NUMBER
1644	

MAIL DATE	DELIVERY MODE
08/24/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.



## UNITED STATES DEPARTMENT OF COMMERCE

## U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10617568	7/11/03	WUCHERPFENNIG ET AL.	DFN-044

FOLEY HOAG, LLP  
PATENT GROUP, WORLD TRADE CENTER WEST  
155 SEAPORT BLVD  
BOSTON, MA 02110

## EXAMINER

DiBrino Marianne

ART UNIT	PAPER
1644	20070806

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

Commissioner for Patents

Please find below a communication from the EXAMINER in charge of this application

This application fails to comply with 37 C.F.R. 1.821-1.825 for the reason(s) listed on the Notice to comply with the sequence rules. The applicants are required to either submit a new CRF and Sequence Listing or a letter authorizing the use of the sequence listing filed with the prior application, along with a statement that the sequences in the two cases are identical.

37 C.F.R. 1.821 (e) A copy of the "Sequence Listing" referred to in paragraph © of this section must also be submitted in computer readable form in accordance with the requirements of § 1.824. The computer readable form is a copy of the "Sequence Listing" and will not necessarily be retained as part of the patent application file. If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference may be made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified.

(f) In addition to the paper copy required by paragraph © of this section and the computer readable form required by paragraph (e) of this section, a statement that the content of the paper and computer readable copies are the same must be submitted with the computer readable form. Such a statement must be a verified statement if made by a person not registered to practice before the Office.

Any inquiry concerning this communication should be directed to Examiner Marianne DiBrino, Art Unit 1644, whose telephone number is 571-272-0842.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

  
Marianne DiBrino, Ph.D.  
Patent Examiner

  
CHRISTINA CHAN  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

<b>Notice to Comply</b>	<b>Application No.</b> 10/617,568	Wucherpennig et al.	
	<b>Examiner</b> Marianne DiBrino	<b>Art Unit</b> 1644	

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other:

**Applicant Must Provide:**

- ☒ An ~~initial or substitute~~ computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An ~~initial or substitute~~ paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

=====

Sequence Listing could not be accepted due to errors.

See attached Validation Report..

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: markspencer

Timestamp: Wed Jun 27 07:16:48 EDT 2007

=====

\*\*\*\*\*

Reviewer Comments:

Please remove the series of ?? at the end of the file.

\*\*\*\*\*

Validated By CRFValidator v 1.0.2

Application No: 10617568

Version No: 2.0

Input Set:

Output Set:

Started: 2007-06-20 16:36:48.516

Finished: 2007-06-20 16:36:48.817

Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 301 ms

Total Warnings: 1

Total Errors: 2

No. of SeqIDs Defined: 36

Actual SeqID Count: 36

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (36)
E 257	Invalid sequence data feature in <221> in SEQ ID (36)
E 257	Invalid sequence data feature in <221> in SEQ ID (36)

# SEQUENCE LISTING

<110> WUCHERPFENNIG, KAI  
SETH, NILUFER

<120> NOVEL COMPOSITIONS AND METHODS FOR THE  
GENERATION OF MHC CLASS II COMPOUNDS BY  
PEPTIDE EXCHANGE

<130> DFS-044.01

<140> 10617568

<141> 2003-07-11

<150> 10/617,568

<151> 2003-07-11

<150> 60/395494

<151> 2002-07-12

<150> 60/397893

<151> 2002-07-22

<160> 36

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 15

<212> PRT

<213> Homo sapiens

<400> 1

Pro Val Ser Lys Met Arg Met Ala Thr Pro Leu Leu Met Gln Ala

1 5 10 15

<210> 2

<211> 13

<212> PRT

<213> Homo sapiens

<400> 2

Ala Ala Met Ala Ala Ala Ala Ala Ala Met Ala Ala

1 5 10

<210> 3

<211> 13

<212> PRT

<213> Homo sapiens

<400> 3

Ala Ala Met Ala Ala Ala Ala Ala Ala Ala Ala

1 5 10

<210> 4  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 4  
Ala Ala Phe Ala Ala Ala Ala Ala Ala Ala Ala Ala  
1 5 10

<210> 5  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 5  
Ala Ser Met Ser Ala Ala Ser Ala Ala Ser Met Ala Ala  
1 5 10

<210> 6  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 6  
Gly Leu Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu  
1 5 10 15

<210> 7  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 7  
Gly Gly Ser Gly Gly Ser  
1 5

<210> 8  
<211> 19  
<212> PRT  
<213> Homo sapiens

<400> 8  
Cys Gly Gly Gly Pro Val Ser Lys Met Arg Met Ala Thr Pro Leu Leu  
1 5 10 15  
Met Gln Ala

<210> 9  
  
<211> 17  
<212> PRT

<213> Homo sapiens

<400> 9

Cys Gly Gly Gly Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala

1 5 10 15

Thr

<210> 10

<211> 13

<212> PRT

<213> Homo sapiens

<400> 10

Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val

1 5 10

<210> 11

<211> 13

<212> PRT

<213> Homo sapiens

<400> 11

Leu Asn Lys Ile Val Arg Met Tyr Ser Pro Thr Ser Ile

1 5 10

<210> 12

<211> 14

<212> PRT

<213> Homo sapiens

<400> 12

Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu Ser Glu Gly

1 5 10

<210> 13

<211> 14

<212> PRT

<213> Homo sapiens

<400> 13

Asp Arg Phe Tyr Lys Thr Leu Arg Ala Glu Gln Ala Ser Gln

1 5 10

<210> 14

<211> 15

<212> PRT

<213> Homo sapiens

<400> 14

Glu Gln Ile Gly Trp Met Thr Asn Asn Pro Pro Ile Pro Val Gly

1 5 10 15

<210> 15  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 15  
Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr  
1 5 10

<210> 16  
<211> 16  
<212> PRT  
<213> Homo sapiens

<400> 16  
Trp Asn Arg Gln Leu Tyr Pro Glu Trp Thr Glu Ala Gln Arg Leu Asp  
1 5 10 15

<210> 17  
<211> 16  
<212> PRT  
<213> Homo sapiens

<400> 17  
Asp Val Pro Lys Trp Ile Ser Ile Met Thr Glu Arg Ser Val Pro His  
1 5 10 15

<210> 18  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 18  
Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro  
1 5 10 15

<210> 19  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 19  
Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu  
1 5 10 15

<210> 20  
<211> 19  
<212> PRT  
<213> Homo sapiens

<400> 20

Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys

1 5 10 15

Ala Arg Ala

<210> 21

<211> 21

<212> PRT

<213> Homo sapiens

<400> 21

Ser Gly Ile Gln Tyr Leu Ala Gly Leu Ser Thr Leu Pro Gly Asn Pro

1 5 10 15

Ala Ile Ala Ser Leu

20

<210> 22

<211> 17

<212> PRT

<213> Homo sapiens

<400> 22

Val Ser Ser Val Ser Ser Gln Phe Ser Asp Ala Ala Gln Ala Ser Pro

1 5 10 15

Ser

<210> 23

<211> 18

<212> PRT

<213> Homo sapiens

<400> 23

Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys

1 5 10 15

Arg Gly

<210> 24

<211> 14

<212> PRT

<213> Homo sapiens

<400> 24

Leu Ile Ala Phe Thr Ser Glu His Ser His Phe Ser Leu Lys

1 5 10

<210> 25

<211> 17

<212> PRT

<213> Homo sapiens

<400> 25

Val Asn Phe Phe Arg Met Val Ile Ser Asn Pro Ala Ala Thr His Gln  
1 5 10 15  
Asp

<210> 26

<211> 15

<212> PRT

<213> Homo sapiens

<400> 26

Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg  
1 5 10 15

<210> 27

<211> 15

<212> PRT

<213> Homo sapiens

<400> 27

Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro  
1 5 10 15

<210> 28

<211> 20

<212> PRT

<213> Homo sapiens

<400> 28

Leu Tyr Gly Ala Leu Leu Leu Ala Glu Gly Phe Tyr Thr Thr Gly Ala  
1 5 10 15  
Val Arg Gln Ile  
20

<210> 29

<211> 20

<212> PRT

<213> Homo sapiens

<400> 29

Phe Tyr Thr Thr Gly Ala Val Arg Gln Ile Phe Gly Asp Tyr Lys Thr  
1 5 10 15  
Thr Ile Cys Gly  
20

<210> 30

<211> 23

<212> PRT

<213> Homo sapiens

<400> 30

Ala Val Arg Gln Ile Phe Gly Asp Tyr Lys Thr Thr Ile Cys Gly Lys  
1 5 10 15  
Gly Leu Ser Ala Thr Val Thr  
20

<210> 31

<211> 20

<212> PRT

<213> Homo sapiens

<400> 31

Ala Val Pro Val Tyr Ile Tyr Phe Asn Thr Trp Thr Thr Cys Gln Ser  
1 5 10 15  
Ile Ala Phe Pro  
20

<210> 32

<211> 19

<212> PRT

<213> Homo sapiens

<400> 32

Ile Ala Ala Thr Tyr Asn Phe Ala Val Leu Lys Leu Met Gly Arg Gly  
1 5 10 15  
Thr Lys Phe

<210> 33

<211> 19

<212> PRT

<213> Homo sapiens

<400> 33

Gln Phe Arg Val Ile Gly Pro Arg His Pro Ile Arg Ala Leu Val Gly  
1 5 10 15  
Asp Glu Val

<210> 34

<211> 20

<212> PRT

<213> Homo sapiens

<400> 34

Gly Lys Asn Ala Thr Gly Met Glu Val Gly Trp Tyr Arg Pro Pro Phe  
1 5 10 15  
Ser Arg Val Val  
20

<210> 35

<211> 20  
<212> PRT  
<213> Homo sapiens

<400> 35  
Trp Tyr Arg Pro Pro Phe Ser Arg Val Val His Leu Tyr Arg Asn Gly  
1 5 10 15  
Lys Asp Gln Asp  
20

<210> 36  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic Peptide

<220>  
<221> MOD\_RES  
<222> (3)  
<223> Xaa = Any Amino Acid

<220>  
<221> MOD\_RES  
<222> (11)  
<223> Xaa = Any Amino Acid

<400> 36  
Ala Ala Xaa Ala Ala Ala Ala Ala Ala Xaa Ala Ala  
1 5 10

??

??

??

??